Background: Systemic Janus kinase inhibitors (JAKi) have emerged as a promising therapeutic class for treating moderate-to-severe atopic dermatitis (AD). While their efficacy and safety have been reported in randomized clinical trials, head-to-head comparisons of these profiles with dupilumab remain limited.
No takes yet. Share an insight, caveat, or question.
Tsai et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: